Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers.
Saved in:
| Title: | Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. |
|---|---|
| Authors: | Mughees M; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tacam M; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tan AW; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pitner MK; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Iles LR; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hu X; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Villodre ES; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Debeb BG; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kogawa T; Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan., Lim B; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Layman RM; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Woodward WA; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ueno NT; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tripathy D; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas., Krishnamurthy S; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qi Y; Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pusztai L; Section of Medical Oncology, Department of Medicine, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut., Wang J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gandhi V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bartholomeusz G; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bartholomeusz C; Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2025 Sep 02; Vol. 24 (9), pp. 1453-1465. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
